Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC

CME
06/02/2025

Listen "Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC "

Descargar episodio Ver en sitio original

Episode Synopsis



Guest: Sarah Sammons, MD

Guest: Carey Anders, MD, FASCO



The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

More episodes of the podcast CME

Updates in Major Depressive Disorder with Insomnia 07/11/2025
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis 03/10/2025
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers 30/09/2025
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers 30/09/2025
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers 30/09/2025
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer 30/09/2025
From Resistance to Response: Evolving Strategies in MDD Management 26/09/2025
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 26/09/2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025 26/09/2025
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 26/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA